Shexiang Tongxin Dropping Pill combined with thrombus aspiration improves myocardial perfusion after PCI in patients with STEMI: the clinical research

Objective:To study the effect of Shexiang Tongxin Dropping Pill combined with thrombus aspiration on improving myocardial perfusion after PCI in patients with STEMI.Methods:A total of 104 patients with STEMI who received emergency PCI combined with thrombus aspiration in our hospital between May 2013 and October 2015 were selected as the research subjects and randomly divided into two groups: observation group received perioperative antiplatelet combined with Shexiang Tongxin Dropping Pill therapy, and the control group received perioperative antiplatelet therapy alone. Before treatment and 3 days after treatment, serum myocardial injury indexes, endothelial injury indexes and RAS system indexes were determined;4 weeks after treatment, serum ventricular remodeling indexes were determined. Results:3 d after treatment, serum CK, CK-MB, cTnI, cTnT, ET-1, vWF, PRA, AngII and ALD levels of both groups were significantly lower than those before treatment while NO level was significantly higher than that before treatment;serum CK, CK-MB, cTnI, cTnT, ET-1, vWF, PRA, AngII and ALD levels of observation group 3 d after treatment were significantly lower than those of control group while NO level was significantly higher than that of control group;4 weeks after treatment, serum PICP, ICTP, PIIINP, HSP47 and GDF-15 levels of observation group were significantly lower than those of control group.Conclusion: Shexiang Tongxin Dropping Pill application during perioperative period of PCI combined with thrombus aspiration can reduce myocardial cell damage and endothelial function injury as well as inhibit RAS system activation and ventricular remodeling.

Shexiang Tongxin Dropping Pill Allieviates Heart Failure via Extracellula Matrix-Receptor Interaction Pathways Based on RNA-Seq Transcriptomics and Experimental Studies

Objective:To investigate the protective mechanisms of Chinese medicine Shexiang Tongxin Dropping Pills(STDP) on heart failure(HF).Methods:Isoproterenol(ISO)-induced HF rat model and angiotensin Ⅱ(Ang Ⅱ)-induced neonatal rat cardiac fibroblast(CFs) model were used in the present study.HF rats were treated with and without STDP(3 g/kg).RNA-seq was performed to identify differentially expressed genes(DEGs).Cardiac function was evaluated by echocardiography.Hematoxylin and eosin and Masson’s stainings were taken to assess cardiac fibrosis.The levels of collagen Ⅰ(Col Ⅰ) and collagen Ⅲ(Col Ⅲ) were detected by immunohistochemical staining.CCK8 kit and transwell assay were implemented to test the CFs’ proliferative and migratory activity,respectively.The protein expressions of α-smooth muscle actin(α-SMA),matrix metalloproteinase-2(MMP-2),MMP-9,Col I,and Col Ⅲ were detected by Western blotting.Results:The results of RNA-seq analysis showed that STDP exerted its pharmacological effects on HF via multiple signaling pathways,such as the extracellular matrix(ECM)-receptor interaction,cell cycle,and B cell receptor interaction.Results from in vivo experiments demonstrated that STDP treatment reversed declines in cardiac function,inhibiting myocardial fibrosis,and reversing increases in Col Ⅰ and Col Ⅱ expression levels in the hearts of HF rats.Moreover,STDP(6,9 mg/mL) inhibited the proliferation and migration of CFs exposed to Ang Ⅱin vitro(P<0.05).The activation of collagen synthesis and myofibroblast generation were markedly suppressed by STDP,also the synthesis of MMP-2 and MMR-9,as well as ECM components Col Ⅰ,Col Ⅲ,and α-SMA were decreased in Ang Ⅱ-induced neonatal rats’ CFs.Conclusions:STDP had anti-fibrotic effects in HF,which might be caused by the modulation of ECM-receptor interaction pathways.Through the management of cardiac fibrosis,STOP may be a compelling candidate for improving prognosis of HF.

麝香通心滴丸预处理对大鼠心肌缺血再灌注损伤的保护作用机制

目的:观察麝香通心滴丸预处理对大鼠心肌缺血再灌注(I/R)损伤后心肌细胞和血管的保护作用及潜在机制。方法:将60只雄性SD大鼠随机分为假手术组(Sham组)、I/R组、麝香通心滴丸组(SXTX组)和阳性组,每组15只。SXTX组以18.90 mg/(kg·d)的浓度灌胃;阳性组以尼可地尔1.35 mg/(kg·d)的浓度灌胃;Sham组和I/R组给予等体积去离子水灌胃。各组均灌胃1周后,行冠状动脉前降支结扎-松解手术,除Sham组外其余各组大鼠结扎左冠状动脉前降支30 min后,再灌注120 min,构建心肌I/R模型。通过心肌苏木精-伊红(HE)染色、心肌Masson染色观察大鼠心肌组织及血管改变;电镜观察心肌细胞和血管的超微结构改变;免疫组织化学法观察血管相关蛋白低氧诱导因子-1α(HIF-1α)和血管内皮生长因子(VEGF)表达情况。结果:与Sham组比较,I/R组大鼠心肌细胞坏死和血管损伤明显,心肌组织中HIF-1α表达增加;与I/R组相比,SXTX组心肌细胞和血管病理结构损伤减轻,缺血区心肌组织VEGF含量明显增加。结论:麝香通心滴丸预处理可保护大鼠心肌细胞和血管I/R损伤,可能与上调VEGF蛋白表达、促进缺血区微血管新生有关。

Effect of Shexiang Tongxin Dropping Pills(麝香通心滴丸) on the Immediate Blood Flow of Patients with Coronary Slow Flow

Objective: To observe the immediate effect and safety of Shexiang Tongxin dropping pills(麝香通心滴丸, STDP) on patients with coronary slow flow(CSF), and furthermore, to explore new evidence for the use of Chinese medicine in treating ischemic chest pain. Methods: Coronary angiography(CAG) with corrected thrombolysis in myocardial infarction(TIMI) frame count(CTFC) was applied(collected at 30 frames/s). The treatment group included 22 CSF patients, while the control group included 22 individuals with normal coronary?ow. CSF patients were given 4 STDP through sublingual administration, and CAG was performed 5 min after the medication. The immediate blood ?ow frame count, blood pressure, and heart rate of patients before and after the use of STDP were compared. The liver and kidney functions of patients were examined before and after treatments. Results: There was a signi?cant difference in CTFC between groups(P<0.05). The average CTFC values of the vessels with slow blood ?ow in CSF patients were, respectively, 49.98±10.01 and 40.42±11.33 before and after the treatment with STDP, a 19.13% improvement. The CTFC values(frame/s) measured before and after treatment at the left anterior descending coronary artery, left circumflex artery, and right coronary artery were, respectively, 48.00±13.32 and 41.80±15.38, 59.00±4.69 and 50.00±9.04, and 51.90±8.40 and40.09±10.46, giving 12.92%, 15.25%, and 22.76% improvements, respectively. The CTFC values of vessels with slow ?ow before treatment were signi?cantly decreased after treatment(P<0.05). There were no apparent changes in the heart rate, blood pressure, or liver or kidney function of CSF patients after treatment with STDP(all P>0.05). Conclusions: The immediate effect of STDP in treating CSF patients was apparent. This medication could signi?cantly improve coronary ?ow without affecting blood pressure or heart rate. Our ?ndings support the potential of Chinese medicine to treat ischemic chest pain.

Shexiang Tongxin Dropping Pill（麝香通心滴丸）Protects against Na2S2O4-Induced Hypoxia-Reoxygenation Injury in H9c2 Cells

Objectives: To investigate the protective effects of Shexiang Tongxin Dropping Pill(麝香通心滴丸,STP) on Na2S2O4-induced hypoxia-reoxygenation injury in cardiomyoblast H9c2 cells. Methods: The cell viability and levels of mRNA and protein expression in H9c2 cells were determined following Na2S2O4-induced hypoxia using Hoechst staining, annexin V/propidium iodide(PI) flow cytometry, real-time polymerase chain reaction and Western blot analysis. Results: STP pretreatment signi?cantly increased the viability and inhibited aberrant morphological changes in H9c2 cardiomyoblast cells induced by Na2S2O4 treatment(P<0.05). In addition, STP pretreatment attenuated Na2S2O4-induced hypoxic damage, down-regulated the expression of pro-apoptotic Bax,and up-regulated the expression of anti-apoptotic Bcl-2 in H9c2 cells(P<0.05). Conclusions: STP was strongly cardioprotective in hypoxia-reoxygenation injury by preventing hypoxic damage and inhibiting cellular apoptosis.These results further support the use of STP as an effective drug for the treatment of ischemic heart disease.

Shexiang Tongxin dropping pill(麝香通心滴丸)protects against sodium laurate-induced coronary microcirculatory dysfunction in rats

OBJECTIVE:To investigate the protective effects of Shexiang Tongxin dropping pill(麝香通心滴丸,STDP)in a rat model of coronary microcirculatory dysfunction(CMD).METHODS:Sprague-Dawley rats were allocated randomly into four groups:sham,CMD model,STDP,and nicorandil.After 4 weeks of treatment,CMD was induced by injection of sodium laurate(0.2 m L,2 g/L)into the left ventricle while obstructing the ascending aorta.Rats in the sham group underwent an identical surgical procedure but were administered physiological(0.9%)saline(0.2 m L).Twenty-four hours after surgery,blood samples were collected for biochemical analyses and enzyme-linked immunosorbent assays.Heart tissues were removed for histopathology staining;apoptosis and inflammatory cytokines were examined by Western blotting.RESULTS:The STDP group had a lower level of creatine kinase-myocardial band,lactate dehydrogenase,and cardiac troponin-I than that in the CMD model group.Infiltration of inflammatory cells,myocardial ischaemia,and microthrombosis were relieved in the STDP group compared with CMD model group.Levels of endothelin-1,nuclear factor-kappa B,tumour necrosis factor-α,interleukin-6,interleukin-1β,malondialdehyde,B-cell lymphoma(Bcl)-2-associated X protein,and caspase-3 were lower,and levels of nitric oxide,Bcl-2,and superoxide dismutase were higher,in the STDP group in comparison with the CMD model group.CONCLUSION:STDP pretreatment improved the CMD induced by sodium laurate via anti-inflammatory,anti-apoptosis,and anti-oxidant mechanisms.

Shexiang Tongxin Dropping Pill(麝香通心滴丸)Reduces Coronary Microembolization in Rats via Regulation of Mitochondrial Permeability Transition Pore Opening and AKT-GSK3βPhosphorylation

Objective To investigate the protective effects of Shexiang Tongxin Dropping Pill(麝香通心滴丸,STDP)following sodium laurate-induced coronary microembolization(CME)in rats.Methods Forty rats were divided into 4 groups:the control(sham)group,CME group,low-dose STDP pretreatment group(20 mg·kg^(−1)·d^(−1)),and high-dose STDP pretreatment group(40 mg·kg^(−1)·d^(−1)).The rats were intragastric administrated with STDP 2 weeks before operation.Moreover,the histopathological alterations were observed using optical microscopy and transmission electron microscopy.Antioxidant biomarkers were analyzed by enzyme-linked immunosorbent assay.Mitochondrial functions including the mitochondrial permeability transition pore(mPTP)mtDNA copy number were determined and proteins of AKT/GSK3βwere analyzed by Western blot.Results The rats in the CME group showed a significant increase in the fibrinogen-like protein 2 expression level and mitochondrial dysfunction and a decrease in the expression level of antioxidant biomarkers(superoxide dismutase and catalase,P<0.01 for all).In contrast,the rats in the low-and high-dose STDP pretreatment groups showed a significant decrease in coronary microthrombi(P<0.05);moreover,STDP restored the antioxidant-related protein activities and mitochondrial function,inhibited mPTP opening,decreased AKT-Ser473 phosphorylation,and increased GSK3β-Ser9 phosphorylation(P<0.05 or P<0.01).Conclusion STDP may be useful for treatment of CME,possibly via regulation of mPTP opening and AKT/GSK3βphosphorylation.

基于网络药理学探讨参蛭通心胶囊核心药对人参-水蛭治疗扩张型心肌病的作用机制

目的:基于网络药理学方法探究参蛭通心胶囊核心药对人参-水蛭治疗扩张型心肌病(dilated cardiomyopathy,DCM)的作用机制。方法:通过中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)、BATMAN-TCM数据库获取人参-水蛭药对的活性成分及潜在靶点并导入UniProt数据库对所得基因进行标准化处理;运用人类基因数据库(the human gene database,GeneCards)获取DCM已知靶点;通过绘制韦恩图得到药物与疾病的交集靶点,将药物活性成分及药物-疾病共同靶点等数据导入Cytoscape 3.7.2软件,构建药物-成分-疾病-靶点网络;运用STRING数据库构建蛋白-蛋白互作网络(protein-protein interactions,PPI)并筛选出核心靶点;将核心靶基因导入基因功能注释数据库(the database for annotation visualization and integrated discovery,DAVID)平台对所得交集靶点进行基因本体(gene ontology,GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)通路富集分析,同时利用OmicShare进行数据的可视化分析。结果:经筛选共获得人参-水蛭药对有效成分35个,药物-疾病交集靶点184个,涉及的核心靶点主要有胰岛素、白蛋白、肿瘤坏死因子、内皮一氧化氮合成酶、过氧化物酶体增殖物激活受体、白细胞介素1β等。人参-水蛭的有效成分通过对细胞膜、细胞外间隙、电压门控钙通道复合体等部位的作用、一氧化氮生物合成过程的正调控、细胞间信号传递、对凋亡过程的负调控等过程和CAMP信号通路等在内的多个信号通路协同作用治疗DCM。结论:参蛭通心胶囊的核心药对人参-水蛭可以通过参与调控多成分、多靶点、多通路治疗DCM。

Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention:A randomized controlled trial

Background:High on-clopidogrel platelet reactivity could be partially explained by loss-of-function alleles of CYP2 C19,the enzyme that converts clopidogrel into its active form.Shexiang Tongxin Dropping Pill(STDP)is a traditional Chinese medicine to treat angina pectoris.STDP has been shown to improve blood flow in patients with slow coronary flow and attenuate atherosclerosis in apolipoprotein E-deficient mice.However,whether STDP can affect platelet function remains unknown.Objective:The purpose of this study is to examine the potential effects of STDP on platelet function in patients undergoing percutaneous coronary intervention(PCI)for unstable angina.The interaction between the effects of STDP with polymorphisms of CYP2 C19 was also investigated.Design,participants and intervention:This was a single-center,randomized controlled trial in patients undergoing elective PCI for unstable angina.Eligible subjects were randomized to receive STDP(210 mg per day)plus dual antiplatelet therapy(DAPT)with clopidogrel and aspirin or DAPT alone.Main outcome measures:The primary outcome was platelet function,reflected by adenosine diphosphate(ADP)-induced platelet aggregation and platelet microparticles(PMPs).The secondary outcomes were major adverse cardiovascular events(MACEs)including recurrent ischemia or myocardial infarction,repeat PCI and cardiac death;blood biomarkers for myocardial injury including creatine kinase-MB isoenzyme(CK-MB)and high-sensitive troponin I(hs Tn I);and biomarkers for inflammation including intercellular cell adhesion molecule-1(ICAM-1),vascular cell adhesion molecule-1(VCAM-1),monocyte chemoattractant protein-1(MCP-1)and galectin-3.Results:A total of 118 subjects(mean age:[66.8±8.9]years;male:59.8%)were included into analysis:58 in the control group and 60 in the STDP group.CYP2 C19 genotype distribution was comparable between the 2 groups.In comparison to the control group,the STDP group had significantly lower CKMB(P<0.05)but similar hs Tn I(P>0.05)at 24 h after PCI,lower ICAM-1,VCAM-1,MCP-1 and galectin-3 at 3 months(all P<0.05)but not at 7 days after PCI(P>0.05).At 3 months,the STDP group had lower PMP number([42.9±37.3]vs.[67.8±53.1]counts/μL in the control group,P=0.05).Subgroup analysis showed that STDP increased percentage inhibition of ADP-induced platelet aggregation only in slow metabolizers(66.0%±20.8%in STDP group vs.36.0%±28.1%in the control group,P<0.05),but not in intermediate or fast metabolizers.The rate of MACEs during the 3-month follow-up did not differ between the two groups.Conclusion:STDP produced antiplatelet,anti-inflammatory and cardioprotective effects.Subgroup analysis indicated that STDP inhibited residual platelet reactivity in slow metabolizers only.

麝香通心滴丸联合瑞舒伐他汀治疗冠心病合并高胆固醇血症的效果和对肝功能的影响

目的:研究麝香通心滴丸联合瑞舒伐他汀治疗冠心病(CHD)合并高胆固醇血症的效果和对肝功能的影响。方法:选取2020年6月—2022年6月在上海市嘉定区中心医院住院治疗的60例CHD合并高胆固醇血症患者,按照随机数字表法将其分为两组,每组30例,单一组给予瑞舒伐他汀治疗,联合组在单一组基础上加以麝香通心滴丸治疗,对比两组临床疗效、血脂水平、内皮功能及肝功能。结果:治疗6个月后,联合组总有效率高于单一组,差异有统计学意义(P<0.05);联合组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)均低于单一组,高密度脂蛋白胆固醇(HDL-C)高于单一组,差异均有统计学意义(P<0.05);联合组一氧化氮(NO)高于单一组,内皮素-1(ET-1)低于单一组,差异均有统计学意义(P<0.05);两组谷丙转氨酶(ALT)、谷草转氨酶(AST)均升高,但联合组均低于单一组,差异均有统计学意义(P<0.05)。结论:使用麝香通心滴丸联合瑞舒伐他汀治疗CHD合并高胆固醇血症具有良好效果,能够有效降低患者血脂水平,改善内皮功能,且对肝功能影响较小。

麝香通心滴丸治疗慢性心力衰竭作用机制研究进展

慢性心力衰竭作为各种心脏疾病的晚期阶段,具有住院率高、病死率高的特点,严重影响患者预后。气虚血瘀证是心力衰竭的常见证型,具有益气活血作用的麝香通心滴丸在治疗慢性心力衰竭方面具有积极作用。从临床和基础研究资料来看,麝香通心滴丸可通过抗炎、抑制心肌纤维化和减轻心肌缺血再灌注损伤等多种机制改善心力衰竭,是潜在的心力衰竭治疗药物。未来需要更多大规模随机对照试验,提供更坚实的证据支持。

煤矿水文孔井下启封技术

为了解决钻孔突水事故,对水文孔进行注浆封堵,保证煤矿安全,以同忻煤矿8102工作面作为研究对象,优化井下启封技术,应用高压注浆法对水文孔进行封堵,在8102工作面皮带顺槽采用钻探、巷探的方式明确1602钻孔位置,并对其实施启封技术,成功完成井下封堵操作。现场实践证明,确定施工方案,实施高压注浆、钻探和巷探能够有效落实井下启封技术,确保煤矿生产的安全性,以免出现突水事故,而且还能有效降低成本投入,对同类型的钻孔启封具有一定的参考价值。

盐酸洛哌丁胺联合痛泻宁颗粒对腹泻型肠易激综合征的临床疗效

目的观察盐酸洛哌丁胺联合痛泻宁颗粒对腹泻型肠易激综合征(IBS)的临床疗效。方法收集60例腹泻型IBS患者的临床资料,按照治疗方案的不同将患者分为观察组(盐酸洛哌丁胺与痛泻宁颗粒联用)和对照组(盐酸洛哌丁胺单用),每组30例。治疗4周后,评估并比较2组患者治疗前后腹痛评分、腹泻评分、症状总评分。结果治疗前,2组患者腹痛评分、腹泻评分、症状总评分比较,差异无统计学意义(P>0.05);对照组治疗后的腹痛评分、腹泻评分、症状总评分与治疗前比较,差异无统计学意义(P>0.05);治疗后,观察组腹痛评分、腹泻评分、症状总评分均低于治疗前,且均低于对照组,差异有统计学意义(P<0.05)。用药期间,2组患者均未观察到明显不良反应。结论盐酸洛哌丁胺与痛泻宁颗粒联用对腹泻型IBS患者疗效显著,且用药安全性良好。

麝香通心滴丸联合沙库巴曲缬沙坦对慢性心力衰竭患者的临床疗效观察

目的 观察麝香通心滴丸联合沙库巴曲缬沙坦对慢性心力衰竭(CHF)患者的疗效。方法 选择2020年1月至2021年12月金华市人民医院收治的CHF患者100例,采用随机数字表法分为两组,各50例。对照组口服沙库巴曲缬沙坦钠片,观察组采用麝香通心滴丸联合沙库巴曲缬沙坦钠片治疗。两组治疗周期12周。观察并比较两组患者的临床疗效、心功能指标[左心室舒张末期内径(LVEDd)、左心室射血分数(LVEF)和左心室收缩末期内径(LVESd)],比较两组患者明尼苏达心力衰竭生活质量问卷(MLHFQ)评分、6 min步行试验(6MWT)距离及血清N末端脑钠肽前体(NT-proBNP)水平。结果治疗12周,观察组患者治疗总有效率高于对照组;两组患者LVEDd、LVESd、MLHFQ评分、NT-proBNP水平低于治疗前,而LVEF、6MWT距离高于治疗前;观察组LVEDd、LVESd、MLHFQ评分、NT-proBNP水平低于对照组,而LVEF、6MWT距离高于对照组,差异均有统计学意义(均P<0.05)。结论 麝香通心滴丸联合沙库巴曲缬沙坦对CHF患者疗效显著,患者心功能改善,血清NT-proBNP水平降低。

麝香通心滴丸联合常规治疗对心肌缺血再灌注损伤患者的临床疗效分析

目的探讨麝香通心滴丸联合常规治疗对心肌缺血再灌注损伤(MIRI)患者的临床疗效和相关机制。方法选取96例经冠状动脉介入(PCI)治疗发生MIRI的急性心肌梗死(AMI)患者为研究对象,将其分为联合组和常规组,每组48例。联合组在常规组基础上加用麝香通心滴丸,2组均连续治疗1个月。比较2组治疗前后心功能及心脏病理性重构指标、血清心肌损伤标志物、血清炎症相关指标水平及治疗效果。结果联合组治疗总有效率为97.83%,高于常规组的87.50%,差异有统计学意义(P<0.05);2组患者左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、每搏心输出量(SV)、血清肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)、N-末端脑钠肽前体(NT-ProBNP)较治疗前均有所改善,且联合组较常规组改善效果更显著,差异有统计学意义(P<0.05);2组患者治疗后血清NOD样受体家族3(NLRP3)炎症小体、超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)水平均下降,且联合组低于常规组,差异有统计学意义(P<0.05)。结论麝香通心滴丸联合常规治疗可缓解MIRI患者持续性心肌损伤,改善心功能和心脏病理性重构,治疗效果优于单纯西药治疗。

麝香通心滴丸改善冠脉微栓塞猪心功能及机制探讨

目的 分析麝香通心滴丸对冠脉微栓塞心肌的保护作用,并探讨其相关机制。方法 选用巴马小型猪18只,随机分为假手术对照组(SHAM组,n=6)、冠脉微栓塞模型组(CME组,n=6)、麝香通心滴丸干预组(SXTXDW组,n=6)。检测各组在不同时间,血清肌钙蛋白(TNI)、B型脑钠肽(BNP)、一氧化氮(NO)、一氧化氮及合成酶(NOS)、内皮素(ET-1)水平,心肌病理学,以及左心导管检查测定左心室收缩末压力(LVESP),左心室舒张末压力(LVEDP),左心室射血分数(LVEF)及心肌局部活动异常情况。结果 与SHAM组比较,CME组血清ET-1水平上升、NO、NOS水平下调(P<0.05),心肌组织可见明显微梗死灶、炎性细胞浸润;LVEDP明显升高,LVEF下降,前壁出现明显的局部活动减弱。与CME组比较,SXTXDW组血清ET-1表达水平下降、NO、NOS水平一定程度恢复(P<0.05),心肌组织梗死灶、炎性细胞浸润减轻,左心室功能改善(P<0.05)。结论 麝香通心滴丸可改善冠脉微栓塞心肌损伤,其机制可能与改善内皮功能、促进微血管修复相关。

废弃矿山地质环境恢复治理实践研究——以同心县某煤矿恢复治理工程为例

为科学利用矿产资源,促进矿山经济可持续发展,同时保护地质环境和土地资源,按照“谁开发谁治理,谁破坏谁复垦”的原则,生产单位在完成矿产开发后需要对矿山地质环境进行恢复治理。本文以同心县某煤矿恢复治理工程为例,研究矿区地质环境恢复治理效果,为废弃矿山生态修复及后续管理提供参考。

左西孟旦联合麝香通心滴丸对LVEF减低心力衰竭患者中的应用及对心肌重塑的影响

目的探讨左西孟旦联合麝香通心滴丸在射血分数(LVEF)减低心力衰竭(HFrEF)患者中的应用效果及对心肌重塑的影响。方法选择2021年2月-2022年2月HFrEF患者246例为对象,随机数字表法分为对照组与观察组各123例。对照组采用左西孟旦治疗,观察组联合麝香通心滴丸,两组均完成10 d治疗,比较两组心功能、心肌重塑、炎症指标、血清生化指标及药物不良反应。结果两组治疗前、治疗10 d后IVST无统计差异(P>0.05);两组治疗10 d后心功能得到改善,观察组LVEF及6 MWD水平高于对照组(P<0.05);LVEDd、LVESd、LVPWT水平低于对照组(P<0.05);两组治疗10 d后炎性因子得到明显降低,观察组TNFα、IL-6及hs-CRP水平低于对照组(P<0.05);两组治疗10 d后血清生化指标得到降低;观察组治疗后MMP-9及BNP水平低于对照组(P<0.05);两组用药期间血钾偏低、低血压、腹泻便秘、肝肾异常及血钾升高发生率无统计意义(P>0.05)。结论左西孟旦联合麝香通心滴丸能提升HFrEF患者心功能水平,能减轻心肌重塑,降低炎性因子水平,改善血清生化指标,且未增加药物不良反应发生率,值得推广应用。

麝香通心滴丸联合常规药物治疗急性心肌梗死经皮冠状动脉介入术后患者的效果

目的:观察麝香通心滴丸联合常规药物治疗急性心肌梗死经皮冠状动脉介入术(PCI)后患者的效果。方法:选取2022年5月至2023年6月该院收治的60例急性心肌梗死患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各30例。两组入院后均行急诊PCI治疗,在此基础上,对照组予以常规药物治疗,观察组在对照组基础上联合麝香通心滴丸治疗,两组均持续治疗1个月。比较两组临床疗效,治疗前后心肌标志物指标[心肌肌钙蛋白I(cTnI)、肌红蛋白(Mb)、肌酸激酶同工酶(CK-MB)]水平、血管内皮功能指标[内皮素-1(ET-1)、一氧化氮(NO)]水平,以及不良反应发生率。结果:观察组治疗总有效率为93.33%(28/30),高于对照组的73.33%(22/30),差异有统计学意义(P<0.05);治疗后,观察组cTnI、Mb、CK-MB、ET-1水平均低于对照组,NO水平高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:麝香通心滴丸联合常规药物治疗急性心肌梗死PCI术后患者可提高治疗总有效率,降低心肌标志物指标水平,改善血管内皮功能指标水平,效果优于单纯常规药物治疗。

通心络对高脂血症伴颈动脉粥样硬化的治疗效果

目的:探讨通心络、瑞舒伐他汀钙片,拜阿司匹林联合应用在高脂血症伴颈动脉粥样硬化中的临床价值。方法:选择我院2021年3月—2022年4月收治的高脂血症伴颈动脉粥样硬化患者68例作为研究病例。按照计算机表法将其分为实验组与参照组,每组各34例。参照组用瑞舒伐他汀钙片,拜阿司匹林治疗,实验组在参照组基础上加通心络治疗。比较两组的血脂、血浆Hcy与hs-CRP水平、超声造影增强指数、斑块数量、面积与IMT厚度。结果:实验组TC、TG、LDL-C低于参照组,HDL-C高于参照组(P<0.05)。实验组血浆Hcy与hs-CRP水平低于参照组,实验组DAT高于参照组,AT、E1/dB低于参照组(P<0.05)。实验组斑块数量少于参照组,斑块面积小于参照组,IMT厚度薄于参照组(P<0.05)。结论:通心络联合瑞舒伐他汀钙片,拜阿司匹林联合应用在高脂血症伴颈动脉粥样硬化中的效果确切,可改善血浆血脂水平。